Cmlsupport - cmlsupport.org.uk
General Information:
Latest News:
Cleavage of BCR–ABL transcripts at the T315I point mutation by DNAzyme promotes cell death in imatinib-resistant BCR–ABL cells 7 Aug 2013 | 05:07 pm
J E Kim1,7, S Yoon1,7, B-R Choi1, K P Kim2, Y-H Cho3, W Jung4, D-W Kim5, S Oh6 and D-E Kim1 The BCR–ABL fusion transcript encodes the BCR–ABL tyrosine kinase (TK), which causes chronic myelogenous le...
Emerging Therapeutic Strategies for Targeting Chronic Myeloid Leukemia Stem Cells 29 Jul 2013 | 06:34 pm
Ahmad Hamad, Zeyad Sahli, Maya El Sabban, Maha Mouteirik, and Rihab Nasr Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut 110...
Imatinib Discontinuation in Chronic Phase CML Doesn’t Always Lead to Relapse 26 Jul 2013 | 09:16 pm
By Dave Levitan June 14, 2013 Almost half of patients with chronic-phase chronic myeloid leukemia (CML) who discontinued imatinib(Drug information on imatinib) treatment did not relapse, according t...
State of CML Treatments 26 Jul 2013 | 09:04 pm
By Michael Mauro, MD1, Jerald Radich, MD2 July 25, 2013 1Memorial Sloan-Kettering Cancer Center, New York 2Fred Hutchinson Cancer Research Center, Seattle Interviewed by Anna Azvolinsky, PhD Chro...
EUTOS Score Validated for Predicting Treatment Outcomes With TKI Therapy 15 Jul 2013 | 05:25 pm
By Dave Levitan | July 12, 2013 While tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) in recent years, prognosis of the disease and prediction of...
'CML Horizons' 2013 Report 5 Jul 2013 | 02:59 pm
Read the report from the 11th International Conference for Organisations Representing People with CML. Prague, Czech Republic. 3rd-5th May 2013.
Europe Approves Ponatinib as Orphan Drug for Leukemias - 3 Jul 2013 | 04:44 pm
Zosia Chustecka Jul 02, 2013 The European Commission has granted marketing authorization to ponatinib (Iclusig, Ariad Pharmaceuticals) as an orphan drug for use in certain leukemia patients who have...
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 1 Jul 2013 | 04:13 pm
Michele Baccarani1,*, Michael W. Deininger2, Gianantonio Rosti3, Andreas Hochhaus4, Simona Soverini3, Jane F. Apperley5, Francisco Cervantes6, Richard E. Clark7, Jorge E. Cortes8, François Guilhot9, H...
"Treating Chronic Myeloid Leukemia Improving Management through understanding the patient experiences" 17 Jun 2013 | 07:18 pm
The Chronic Myelogenous Leukemia (CML) Society of Canada is pleased to provide open access to the paper, “Treating Chronic Myeloid Leukemia - Improving Management Through Understanding of the Patient ...
Landmark analysis of 4-year (y) data from ENESTnd. 12 Jun 2013 | 02:45 pm
Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) 2013 ASCO An...
